Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations.

Fulgent Genetics is evolving into a precision medicine player with strong cash reserves, despite expected near-term losses.

Recent advances in RAS-targeted therapies revolutionize treatment for gastrointestinal cancers, promising improved outcomes ...